EUVIMEDEUVIMED entdecken
Crossref

Addition of low-dose antithymocyte globulin to post-transplant cyclophosphamide for effective graft-versus-host disease prophylaxis in peripheral blood stem cell transplantation

Dong Hyun Kim, Sin Young Park, Hyunsoo Cho, Ja Min Byun, Dong-Yeop Shin, Youngil Koh, Inho Kim, Junshik Hong

Transplant Immunology · 2026

DOI: 10.1016/j.trim.2026.102438 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Immunology, 2026. Verfasst von Dong Hyun Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Department of Translational Medicine, Seoul National U…. Hauptthemen laut MEDLINE: Graft vs Host Disease, Antilymphocyte Serum, Cyclophosphamide, Peripheral Blood Stem Cell Transplantation. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Post-transplant cyclophosphamide (PTCy) is central to graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic cell transplantation (allo-HCT); however, there remains an opportunity for further advancement. OBJECTIVE: This study aimed to evaluate the efficacy of dual T-cell depletion using low-dose PTCy and antithymocyte globulin (ATG) for GVHD prophylaxis in peripheral blood allo-HCT. METHODS: Patients with acute leukemia or myelodysplastic syndrome (MDS) who received either PTCy or ATG/PTCy for GVHD prophylaxis were included. Transplant outcomes were compared between the PTCy and ATG/PTCy groups. In the ATG/PTCy group, rabbit ATG (3.0-4.0 mg/kg according to recipient absolute lymphocyte count) and dose-attenuated PTCy (50 mg/kg on day +3 and 30 mg/kg on day +4) were administered. RESULTS: A total of 97 patients were included. Neutrophil engraftment was faster in the ATG/PTCy group. There were no significant differences between the two groups in overall survival, relapse-free survival, or GVHD-free, relapse-free survival. The cumulative incidences of relapse, non-relapse mortality, and grade III-IV acute GVHD were comparable between the two groups. In contrast, the ATG/PTCy group showed a lower incidence of moderate-severe chronic GVHD (2-year: 3.7% [95% CI, 0.7%-11.4%] vs. 17.0% [95% CI, 7.3%-30.2%], P = 0.046). On multivariate analysis, ATG/PTCy was independently associated with a lower risk of moderate-severe cGVHD, but not with relapse, non-relapse mortality, or survival outcomes. CONCLUSION: The addition of low-dose ATG to PTCy may further reduce moderate-severe chronic GVHD compared with PTCy alone, without increasing the risk of relapse or NRM, resulting in improved GRFS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseAntilymphocyte SerumCyclophosphamidePeripheral Blood Stem Cell TransplantationMyelodysplastic SyndromesImmunosuppressive AgentsHumansFemaleMiddle AgedMaleAdultAnimalsTransplantation, HomologousAdolescentAgedYoung AdultRabbitsRetrospective StudiesLymphocyte Depletion

Stichwörter der Autor:innen

Allogeneic hematopoietic cell transplantationAntithymocyte globulinDual T-cell depletionGraft-versus-host diseasePost-transplant cyclophosphamide

Substanzen

Antilymphocyte SerumCyclophosphamideImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Department of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic ad…
  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea; Cancer Research Institute, Seou…

Zitieren

APA

Kim, D. H., Park, S. Y., Cho, H., Byun, J. M., Shin, D. Y., Koh, Y., Kim, I., & Hong, J. (2026). Addition of low-dose antithymocyte globulin to post-transplant cyclophosphamide for effective graft-versus-host disease prophylaxis in peripheral blood stem cell transplantation. Transplant Immunology. https://doi.org/10.1016/j.trim.2026.102438

Vancouver

Kim DH, Park SY, Cho H, Byun JM, Shin DY, Koh Y, et al. Addition of low-dose antithymocyte globulin to post-transplant cyclophosphamide for effective graft-versus-host disease prophylaxis in peripheral blood stem cell transplantation. Transplant Immunology. 2026. doi:10.1016/j.trim.2026.102438

BibTeX
@article{Kim2026,
  author = {Kim, Dong Hyun and Park, Sin Young and Cho, Hyunsoo and Byun, Ja Min and Shin, Dong-Yeop and Koh, Youngil and Kim, Inho and Hong, Junshik},
  title = {Addition of low-dose antithymocyte globulin to post-transplant cyclophosphamide for effective graft-versus-host disease prophylaxis in peripheral blood stem cell transplantation},
  journal = {Transplant Immunology},
  year = {2026},
  doi = {10.1016/j.trim.2026.102438}
}
Kostenlos starten →